N-[(1S)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-carbamic acid 1,1-dimethylethyl ester

In House Impurity
Print | Download pdf
Stock Status : <%stockStatus%>

<%deliveryStatus%>

Catalogue number: PA 02 0791011
Chemical name: N-[(1S)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-carbamic acid 1,1-dimethylethyl ester

CAS Number:

1187479-72-6

Category: impurities,metabolites,pharmaceutical standards,intermediates,fine chemicals
Synonyms:

Tert-Butyl ((S)-1-(((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate;

Molecular form: C29H45BN2O5
Appearance: NA
Mol. Weight: 512.5
Storage: 2-8°C Refrigerator
Shipping Conditions: Ambient
Applications: N-[(1S)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-Carbamic Acid 1,1-Dimethylethyl Ester is an intermediate in the synthesis of bortezomib (B675700).Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer.
BTM: NA

N-[(1S)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-carbamic acid 1,1-dimethylethyl ester

1187479-72-6
| Sample COA MSDS

Enquire for N-[(1S)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-carbamic acid 1,1-dimethylethyl ester

Order Product

Search by Keywords – Buy 1187479-72-6 | Purchase 1187479-72-6 | Order 1187479-72-6 | Enquire 1187479-72-6 | Price of 1187479-72-6 | 1187479-72-6 Cost | 1187479-72-6 Supplier | 1187479-72-6 Distributor | 1187479-72-6 Manufacturer | 1187479-72-6 Exporter

cart bucket

×

wishlist

×
Proceed